Vysis MET CDx FISH kit or RealTime HIV-1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $145,884 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $145,884 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A clinical retrospective trial to evaluate the reproducibility of the Vysis MET CDx Fluorescence in-situ Hybridization (FISH) Kit assay in formalin-fixed paraffin-embedded non small cell lung cancer (NSCLC) specimens | Abbott Laboratories | $145,884 | 0 |
Top Doctors Receiving Payments for Vysis MET CDx FISH kit or RealTime HIV-1
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Grand Rapids, MI | $145,884 | 2 |
Manufacturing Companies
- Abbott Laboratories $145,884
Product Information
- Type Device
- Total Payments $145,884
- Total Doctors 0
- Transactions 2
About Vysis MET CDx FISH kit or RealTime HIV-1
Vysis MET CDx FISH kit or RealTime HIV-1 is a device associated with $145,884 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2018. In 2018, $145,884 was paid across 2 transactions to 0 doctors.
The most common payment nature for Vysis MET CDx FISH kit or RealTime HIV-1 is "Unspecified" ($145,884, 100.0% of total).
Vysis MET CDx FISH kit or RealTime HIV-1 is associated with 1 research study, including "A clinical retrospective trial to evaluate the reproducibility of the Vysis MET CDx Fluorescence in-situ Hybridization (FISH) Kit assay in formalin-fixed paraffin-embedded non small cell lung cancer (NSCLC) specimens" ($145,884).